BURLINGTON — Life science conglomerate LabCorp is now offering antibody tests for the virus that causes COVID-19 starting today.
The Burlington-based firm said there will be no upfront out-of-pocket costs to people who receive an order for a test through a doctor or healthcare provider, including telemedicine providers.
The COVID-19 antibody blood tests detect the presence of antibodies to the virus and can help identify individuals who have been exposed to the virus.
The tests will be administered at tens of thousands of doctors’ offices across the US, and at LabCorp’s nearly 2,000 patient service centers, including LabCorp at Walgreens locations.
Results will be available to the ordering healthcare provider within one to three days after the date of specimen pick up. They are also available to patients in the LabCorp Patient mobile app.
“We are bringing the full force of LabCorp’s science and testing capabilities to serve individuals across the US whether they had the virus or believe they have the virus,” said Adam Schechter, president and CEO of LabCorp, in a statement.
“We stand with all Americans, healthcare workers, and those on the frontlines who are helping people in need.”
LabCorp began antibody blood testing on a limited basis to high-priority healthcare workers in late-March and currently has capacity to perform over 50,000 antibody tests per day.
By mid-May, LabCorp said it expects to be able to perform 200,000 tests per day as more tests and testing platforms receive U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA).
LabCorp stressed that while antibody tests are helpful to understand if an individual has developed antibodies and a potential immune response, antibody testing should not be used as the sole basis to diagnose or exclude infection.
“Knowing a patient’s results might be useful in the determination of important decisions, such as the ability for hospital staff to care for patients,” the firm said in its release.
These tests have not been reviewed by the FDA but are being offered by LabCorp in accordance with the public health emergency guidance issued by the FDA on March 16.
Original Article Source: WRAL TechWire